VRSN — VeriSign, Inc.

Sentiment turned constructive after the 2026-07-23 Q2 print: revenue of $434.6M (+6% YoY), operating income of $296.3M, EPS of $2.38 (+7.7% YoY) and total .com/.net registrations of 179.1M (+5.1% YoY), with FY2026 revenue guidance of $1.745-1.755B reaffirmed. Two visible catalysts followed: the board expanded the remaining buyback authorization to $1.50B (0.7M shares repurchased for $197M in Q2 alone), and in July 2026 the long-awaited .web TLD was delegated into the DNS root zone with general availability targeted for early 2027. Sell-side is skewed positive (9 Buy / 5 Hold / 1 Sell) with price targets clustered at $332.50-$348 against the $292.71 price on 2026-09-13. This is measured optimism rather than a melt-up: RSI of 55.89 is neutral, the shares trade at roughly 30x forward EPS, and the CEO/Chairman's routine 10b5-1 sales (e.g. 3,300 shares at ~$250-251 in late June, with further sales in August/September) temper the tape.

VeriSign is a stable mid-single-digit compounder, not an inflection story. Revenue went from $376.3M in Q3 2023 to $434.6M in Q2 2026, a ~4.9% CAGR, and grew sequentially in every one of the last 12 quarters. YoY revenue growth accelerated through the cycle — +3.8% (Q3 2024), +3.9% (Q4 2024), +4.7% (Q1 2025), +5.9% (Q2 2025), +7.3% (Q3 2025), +7.6% (Q4 2025) — and has since settled into a ~6% groove: +6.6% in Q1 2026 and +6.0% in Q2 2026. That step-down from 7.6% to 6.0% is a blip within a range, not a structural deceleration; there is no evidence of domain-demand deterioration (registrations still +5.1% YoY). Operating margin has been remarkably constant, holding a tight 67.0%-68.8% band across all 12 quarters (68.2% in Q2 2026, 68.8% in Q2 2024, 67.0% in Q4 2025), so there is neither margin expansion nor compression to trade. EPS has compounded 8-11% YoY every quarter without exception (Q2 2026 $2.38 vs Q2 2025 $2.21 vs Q2 2024 $2.01; Q1 2026 $2.34 vs Q1 2025 $2.10 vs Q1 2024 $1.92) — but roughly a third of that comes from share-count reduction, not operating leverage. Note the Q4 2023 distortion: EPS of $2.60 with net income of $264.7M exceeding operating income of $256.3M was a one-off tax benefit, not operating strength; strip it out and the trend is smooth. FCF quality is excellent, with TTM free cash flow of $1,066.1M at 6/30/26 versus $950.0M a year earlier (+12.2%), against quarterly capex that has never exceeded $28.6M.

As of 2026-09-13, at $292.71, VeriSign is fairly valued, not cheap. Trailing P/E is 31.7x versus a 5-year average of 29.7x, and P/S is 15.5x versus a 5-year average of 15.56x — essentially dead-on its own history on both measures, so there is no mean-reversion cushion in either direction. Forward P/E is roughly 29.9x on next-FY EPS of $9.79, and the PEG of 3.17 is a lot to pay for ~5-6% revenue and ~8% EPS growth. P/B (-11.8x), ROE (-38%) and the reported ROIC are meaningless artifacts of -$2.254B of stockholders' equity, a deliberate consequence of debt-funded buybacks ($1.785B of long-term debt at 6/30/26). On absolute business quality the multiple is defensible — 88.5% gross margin, 67.9% operating margin, 49.8% net margin, ~94% FCF conversion and a beta of 0.699 — but the historical range says you are paying full price for that quality, and the deterministic score's 'Neutral vs. its own history' label is the right read.

The market is paying ~30x forward for next-FY EPS of $9.79 that is itself only about 4-5% above the $9.36 trailing figure — meaning the price already embeds the buyback-driven EPS compounding rather than a growth inflection. Three things to watch in each print: (1) net .com/.net additions and whether FY2026 revenue guidance of $1.745-1.755B gets raised rather than merely reaffirmed — guidance has been reaffirmed twice, so a raise is the genuinely under-priced upside; (2) the split between operating growth and financial engineering, since 0.7M shares were retired for $197M in Q2 2026 against a ~90.4M share count, meaning roughly 3%/yr of EPS growth comes from buybacks partly funded with $1.785B of debt; (3) the realistic return math — ~6% revenue growth + ~3% share shrink + 1.17% indicated yield implies a high-single-digit to low-double-digit annualized total return, well short of the ~14-19% implied by the $332.50-$348 price targets. Those targets require the multiple to re-rate toward 34x, which only happens if the antitrust overhang clears or .web materially beats expectations. Conversely, the annuity-like renewal base and low beta mean a catastrophic downside scenario is unlikely; a guidance cut or an adverse antitrust ruling is what would break the multiple.

As of 2026-09-13, VRSN's RSI(14) stood at 55.89 — neutral, with neither an overbought nor an oversold signal. The stock was in a confirmed uptrend, trading +2.12% versus its 20-day SMA, +3.90% versus its 50-day and +11.5% versus its 200-day, with the moving averages stacked in bullish order. Trailing returns of +0.2% (1 week), +3.45% (1 month), +4.58% (3 months) and +22.68% (6 months) show momentum that has cooled off from the spring run without reversing, and at $292.71 the shares sat roughly 81% of the way up a 52-week range of $208.86-$312.48. Timing implication: there is no oversold condition to wait for, but also little margin of safety chasing at $293 — the 50-day (~$282) and 200-day (~$262) are the logical add levels, and ~$312 is the nearest resistance.

• Regulatory and antitrust overhang: a class-action antitrust suit (Hagens Berman filings) alleging monopolistic control over .com registry pricing and the presumptive right of renewal, plus ongoing ICANN and U.S. Department of Commerce oversight — the single biggest determinant of VeriSign's long-term pricing power.
• Interest rates and credit conditions: $1.785B of long-term debt against deliberately negative equity (-$2.254B at 6/30/26) and a current ratio of only 0.591 means refinancing costs flow straight to EPS and buyback capacity is rate-sensitive.
• Defensive/low-beta rotation: a 0.699 beta and annuity-like renewal revenue make VRSN a bond-proxy-like holding that attracts institutional money in risk-off periods but lags in strong risk-on rallies — part of why the 6-month gain (+22.7%) trails high-beta software.
• Secular domain demand: digital transformation and registrar marketing keep registrations growing (~179.1M .com/.net names, +5.1% YoY), though AI-assisted website creation and alternative naming conventions are a long-dated substitution question.
• Concentration and counterparty structure: revenue depends on a small set of large registrars and on a single registry agreement framework, so any renegotiation or change in the ICANN/Commerce framework is a systemic risk rather than a company-specific one.

• Q3 2026 earnings, expected late October 2026: the key question is whether net .com/.net additions continue to outpace historical seasonality and whether FY2026 revenue guidance of $1.745-1.755B is raised rather than merely reaffirmed.
• .web commercial launch in early 2027: delegated to the DNS root zone in July 2026, with general availability rolling out in early 2027 — the first genuinely new incremental revenue vector in years; watch registrar distribution and pricing at launch.
• Scheduled .net price increases effective March 2027, plus contractual .com price escalation provisions in the registry agreement — direct, high-margin ARPU step-ups.
• Continued share repurchases: 0.7M shares for $197M in Q2 2026, with $1.50B of remaining authorization equal to roughly 5.7% of the $26.5B market cap — a mechanical, multi-year EPS tailwind.
• Resolution or escalation of the antitrust litigation: a favorable outcome would likely compress the regulatory discount embedded in the multiple; an adverse ruling or a DOJ action would do the opposite.

• Antitrust and regulatory risk: the Hagens Berman class action and broader ICANN/Commerce scrutiny could constrain .com pricing or invite structural remedies, undermining the annuity economics that justify a ~30x multiple.
• Capital structure: negative stockholders' equity of -$2.254B, $1.785B of long-term debt and a 0.591 current ratio mean buybacks have been partly debt-funded; a rate shock or an FCF stumble would pressure both interest expense and the repurchase engine.
• Growth/valuation mismatch: 5-6% revenue growth at ~30x forward earnings and a 3.17 PEG leaves almost no room for a miss — the multiple, not the earnings, carries most of the downside risk.
• Domain growth dependency: registration growth depends on registrar promotional activity and wholesale pricing, so a registrar price war or a slowdown in net additions would hit the revenue trajectory that the buyback math depends on.
• Insider selling: routine Rule 10b5-1 sales by Executive Chairman/CEO D. James Bidzos (including 3,300 shares at ~$250-251 in late June and further sales in August/September) add steady supply and can weigh on sentiment even though the plans are pre-arranged.

VeriSign is a genuinely excellent, wide-moat business — 88.5% gross margin, 67.9% operating margin, ~$1.07B of TTM free cash flow on essentially no capital spending, ~75%+ renewal economics, and consistent ~6% revenue / ~8-11% EPS growth — but at $292.71 on 2026-09-13 and roughly 30x forward earnings, that quality is already in the price, with the P/E and P/S both sitting right on their 5-year averages. This is a buy-on-weakness holding, not a bargain: the realistic return path is high-single-digit to low-double-digit annualized (growth plus buyback plus the 1.17% indicated yield), not the 14-19% implied by the $332.50-$348 analyst targets. Add toward the 50-day (~$282) or 200-day (~$262), or on any clarity that resolves the antitrust overhang; do not chase at $293 with the stock already 11.5% above its 200-day.

Primary method: 31x applied to my NTM EPS estimate of $9.85 (H1 2026 actual EPS of $4.72 annualized forward at ~6% revenue growth plus ~3%/yr share-count reduction), giving 31 x 9.85 = $305 — a modest premium to VeriSign's own 5-year average P/E of 29.7x, justified only by the .web launch and the March 2027 .net price step-up. Cross-checks: (a) $1.13B of NTM free cash flow at 25-26x EV/FCF implies ~$28.3-29.4B of enterprise value, less $0.94B of net debt (cash of $840.9M against $1,785.1M of long-term debt) and 90.4M shares, gives roughly $300-$315; (b) a simplified 5-year DCF (6% FCF growth fading to 3% terminal, 7.5-8% discount rate) yields $270-$285. At $305 the implied EV/FCF is ~25x, which I consider the fair clearing level for a low-beta, ~6%-growth, 68%-operating-margin monopoly-like asset with a live antitrust overhang.